77.4 F
New York
Thursday, July 29, 2021

Gilead Sciences [NASDAQ: GILD] To Start Testing Of Inhalable Version Of Remdesivir For COVID-19

Must read

Digital Realty [NYSE: DLR] Considering Developing 64 MW Facility in South Korea

Digital Realty Trust, Inc. has shown its intention to build the 64-megawatt facility in Seoul, South Korea. The firm has decided that the...

Why Shares of IZEA Worldwide [NASDAQ: IZEA] Skyrocketing Today?

Shares of IZEA Worldwide, Inc. surged 8.10% at the time of writing on Wednesday. The strong performance of the firm has highlighted the...

BIT Mining [NYSE: BTCM] Ink Purchase Agreement to Buy Bitcoin Mining Machine

BIT Mining Limited has inked a purchase agreement to increase the fleet of bitcoin mining machines. As per the new purchase agreement, the...

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Dyadic International, Inc. disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been...

Gilead Sciences, Inc. [NASDAQ: GILD] has started the human testing of the inhaled version of coronavirus drug remdesivir. The company aimed to make the treatment possible which not involve hospitalization.

FDA has given an emergency authorization to Gilead Sciences, Inc. for the use of investigational drug remdesivir for the treatment of COVID-19 in May. According to the company, the testing for the inhaled version of remdesivir will enroll 60 healthy Americans between the age of 18 and 45. Gilead Sciences will test the drug only on those patients who have the disease but not progressed to the point where they need hospitalization.

Remdesivir is the antiviral drug that is being studied in multiple phases. In the current health emergency, the approval for this drug varied in countries. In the countries, where remdesivir is not approved by the authorities it is used as an investigational drug and its efficacy and safety have not been confirmed yet.

Shares of Gilead, Sciences, Inc. [GILD] plummeted 1.06% in the trading on Wednesday after it announced the phase 1a testing of the inhaled version of remdesivir. This company had a trading volume of 6.2 million as compared to the average volume of 16.44 million.

Gilead Sciences, Inc. has a Gross Margin of 79.40%, a Profit Margin of 21.80%, and an Operating Margin of 19.60%. GILD’s return on assets, equity and investment is 8.10%, 22.60%, and 9.50%, respectively.

More articles

Latest article

Binance, FTX Cut Leverage Limits on Crypto Futures Trading to 20x

Two major cryptocurrency trading platforms Binance Futures and FTX disclosed on Monday that they both have made a remarkable decision related to the crypto...

TD Holdings [NASDAQ: GLG] Inks Letter of Intent with Guangdong Jinbochuang

TD Holdings, Inc. has inked a letter of intent (LOI) with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. and (Jinbochuang) and Hunan Jinmeike...

ASGN [NYSE: ASGN] Acquire IndraSoft Inc

ASGN Incorporated disclosed that it has acquired IndraSoft Inc. IndraSoft Inc has gained recognition as a prominent cybersecurity and digital transformation solutions offeror...

Link Reservations Decides to Accept Bitcoin/Crypto Payments

Link Reservations Inc disclosed Friday that it has decided to start accepting Bitcoin and cryptocurrency payments. This is the major breakthrough for the firm...

Athene [NYSE: ATH] Announces Acquisition of Foundation Home Loans

Athene Holding Ltd. disclosed on Thursday that it has inked a definitive agreement to purchase Foundation Home Loans (FHL). FHL had a £3...

Ping [NYSE: PING] and Anexinet Announces Partnership

Ping Identity Holding Corp. and Anexinet Corporation have both entered into a partnership agreement. The collaboration will integrate Ping Identity’s centralized Identity Access...

Digital Realty [NYSE: DLR] and Brookfield Announces Joint Venture

Digital Realty Trust, Inc.   and Brookfield Infrastructure Partners L.P. and its institutional partners disclosed on Wednesday that they have launched a 50/50 joint...

Red Cat [NASDAQ: RCAT] Announces Acquisition of Teal Drones

Red Cat Holdings, Inc. has inked an agreement on Tuesday to buy Teal Drones in an all-stock transaction. This acquisition will add Teal...